Ballicules.com

Lubiprostone

AMITIZA

What it isChloride channel type 2 activator increasing intestinal fluid; chronic constipation and opioid-induced constipation.

Why this oneIn opioid constipation it preserves analgesia without the withdrawal risk of peripherally acting opioid antagonists.

What limits itNausea is dose-limiting and reduced by taking it with food. It does not work for methadone-induced constipation.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Chronic idiopathic constipation (CIC)Adults24 mcg BID24 mcg BID24 mcg BID
Opioid-induced constipation (OIC)Adults24 mcg BID24 mcg BID24 mcg BID
Irritable bowel syndrome with constipation (IBS-C)Adult women8 mcg BID8 mcg BID8 mcg BID

Renal Undefined

Hepatic CIC/OIC: moderate (Child-Pugh B) 16 mcg BID, severe (C) 8 mcg BID. IBS-C: moderate no adjustment, severe 8 mcg QD. Mild (A): no adjustment.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Limited human data; animal data show dose-dependent fetal loss (likely secondary to maternal toxicity).

Lactation No human data; monitor breastfed infant for diarrhea.

NO BOXED WARNINGS

Principal riskNausea, dose-limiting

Cost, est. cash$5–$150/month

Generic entry2021

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk0 / 4

Legacy pregnancy categoryC

Defining liabilityDiarrhea, dehydration and electrolyte disturbance, especially with excessive or prolonged use.

Mechanism of action: Lubiprostone ballicule

Lubiprostone ballicule: receptor binding, kinetics and half-life diagram

Open Lubiprostone in the interactive console ↗